论文部分内容阅读
以二乙基亚硝胺（DEN）诱发大鼠肝癌，正常大鼠和肝癌大鼠分别腹腔注射干扰素（IFNα—2b）、卡介苗（BCG）或二者联用。从正常大鼠和肝癌大鼠体内分离出高纯度的血单核细胞、肺、脾和腹腔内的巨噬细胞，体外分别与人肝癌细胞联合培养，测定培养液中的IL—1的活性。此外，尚在肝癌大鼠体内分离出高纯度的血单核细胞、肺、脾和腹腔内的巨噬细胞，体外受IFNα—2b、BCG或二者联合作用后，同上测定培养液中的IL—1的活性。结果显示：IFN0α—2b或BCG均可促进上述单核巨噬细胞释放IL—1，并均以两者联用的效果最佳，四种单核巨噬细胞释放IL—1为对照组的1．09～2．04倍不等。本结果提示肝癌病人进行免疫治疗时，应考虑两种免疫制剂联合应用。
Rat liver cancer was induced with diethylnitrosamine (DEN), and normal rats and liver cancer rats were injected intraperitoneally with interferon (IFNα-2b), BCG or both. High purity blood mononuclear cells, lungs, spleen, and intraperitoneal macrophages were isolated from normal rats and liver cancer rats and cultured in vitro with human hepatoma cells to determine IL-1 activity in the culture medium. In addition, high-purity blood mononuclear cells, lungs, spleen, and intraperitoneal macrophages were also isolated from liver cancer rats. After IL-2b, BCG, or a combination of the two was used in vitro, the IL in the culture fluid was determined as above. -1 activity. The results showed that both IFNα-2b or BCG could promote the release of IL-1 from mononuclear phagocytes, and both of them had the best effect. The release of IL-1 by four mononuclear macrophages was the control group1 .09 to 2.04 times. This result suggests that when immunotherapy is performed on liver cancer patients, the combination of two immunogenic agents should be considered.